Indian dual insulin price cap policy favors multinationals: Biocon chief
This article was originally published in Scrip
Executive Summary
Biocon's chairperson and managing director, Kiran Mazumdar-Shaw, has lashed out at India's dual ceiling price approach for human insulin - a lower cap for domestic manufacturers and a higher one for the imported finished form of multinationals - which she believes hurts local firms.